MenuMENU
Clinical Management > Useful Resources > Positions & Guidelines

ACMT Position Statements

Position Statements

These statements are intended to summarize a vast body of reviewed literature and expert opinion in a 1-2 page document with a small number (8-10) of references. The intended audience is both college members and others interested in the given topic. We see these as providing the basis for response to media, patients, and the starting point for further reading. They are not intended to be exhaustive treatises; however they should recognize areas of controversy, providing a position backed by legitimate science. When applicable, each statement should include: * Introduction Introduce the topic or controversy and provide background regarding context (of exposure, contact, etc.) and purpose. * Data Where appropriate, this should be broken out into basic science, animal, human (epidemiologic, case-control, anecdotal) components. While raw numbers and summaries of studies are not required, any relative risk data should be referenced. * Conclusions Brief statement summarizing position of College. While not required, it is encouraged that authors use terms of the Bradford Hill criteria whenever imputing or refuting causation issues (strength of association, specificity, dose response, temporality, coherence, consistency, etc.). * References Major reviews and critiques. Any specific data cited in the statement should be referenced by author in the body of the statement. * Date Include the date of submission (month/year) and any revisions noted. All position statements will be edited by the committee and then referred to the board. Any comments will be reviewed by the authors and the committee. Once endorsed by the board, they will be posted on the ACMT web site and published in an issue of JMT. All position statements will be introduced by a disclaimer indicating that while individual practitioners may differ, this is the position of the college at the time written, after a review of the issue and pertinent literature. All statements should be reviewed on a periodic basis (every 3 years) and as needed when new data or questions arise. The original author(s) will be asked to address any questions, indicating the date of any revisions on the statement. Each author must sign a disclosure form discussing any potential sources of bias and conflict of interest.
 ACMT Position Statement: Duration of Intravenous Acetylcysteine Therapy Following Acetaminophen Overdose March 8, 2016
 ACMT Position Statement: Safety Issues Regarding Prescription Fentanyl Products February 4, 2016
 ACMT Position Statement: The Use of Methadone as an Analgesic January 8, 2016
 Safety Issues Regarding Prescription Opioids January 5, 2016
 ACMT Ethics Statement November 9, 2015
 Guidance Document: Management Priorities in Salicylate Toxicity
 Medical Toxicologist Participation in Medication Management and Safety Systems
 Antidote Shortages: Impact and Response
 Pressure Immobilization After North American Crotalinae Snake Envenomation
 The Role of a Medical Toxicologist for Assistance in the Treatment of Alcohol Withdrawal Syndrome
 Interpretation of Urine Analysis for Cocaine Metabolites
 Institutions Housing Venomous Animals
 Recognition of Medical Direction and Support of Poison Center Activities
 Interim Guidance for the Use of Lipid Resuscitation Therapy
 American College of Medical Toxicology Code of Ethics for Medical Toxicologists
 Post-Chelator Challenge Urinary Metal Testing
 Dietary Supplements
 IOM Report on Thimerosal and Autism
 Material Safety Data Sheets
 Hospital Privileges for Physicians Practicing Medical Toxicology
 Care of Poisoned Patients
 Institute of Medicine Report on Damp Indoor Spaces and Health
RSS rss